Ctxr stock forecast analyst consensus for CTXR stock

Analyst consensus for CTXR stock forecast remains in speculative territory, with most coverage emphasizing binary risks tied to trial outcomes. This is typical for biotech names without significant existing revenue streams. H.C. Wainwright initiated coverage of Arcutis Biotherapeutics (ARQT) with a Buy rating and $19 price target. The firm expects Zoryve, across its family of strengths and presentations, to become one of the leading topical agents for treating inflammatory dermatology conditions including psoriasis, atopic dermatitis, and seborrheic dermatitis with "blockbuster" peak sales potential. Of these two pipeline candidates, Lymphir is the farthest along. Citius submitted the BLA last year, and in July received a Complete Response Letter. The company responded, addressing the FDA’s concerns, and in March of this year received notice that the application had been accepted for review with a PDUFA date of August 13. CTXR stock forecast models project incremental gains if sector M&A activity accelerates. Acquisition rumors can significantly reprice micro-cap biotech valuations within days, a common pattern in past deal cycles.